Sumitomo Chemical India Ltd
SUMICHEMSumitomo Chemical India Ltd is coiled. The quarters are improving, yet the P/E sits at the 11th percentile of its own 6-year range — the business is moving before the market.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (9 weeks in) while the P/E sits at the 11th percentile of its own 6-year range. Underneath, the last four quarters read improving — profit +20.8% year on year, and 117% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sumitomo Chemical India Ltd trades at ₹476, in a confirmed uptrend and 9 weeks into that stage. That is −1.5% against its own 200-day average. It sits at 53% of a 52-week range of ₹375 to ₹565. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 10 straight weeks.
Today the stock is in a confirmed uptrend — week 9 of stage 2, confirmed. At ₹476 it trades −1.5% versus its 200-day average and sits at 53% of its 52-week range (₹375–₹565).
Against the market, two honest reads. Cumulative: over the last 6.6 years the stock moved +106% while the NIFTY 500 moved +130% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Sumitomo Chemical India Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: EARLY_EXPANSION. Still open: A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure.
Our read, 22 August 2026. Earnings are recovering through specialty mix and calibrated pricing, but the trailing valuation rests on elevated margins and carries a peak-margin value-trap risk.
From the numbers. The operating and price curves indicate early expansion with price below its prior peak. This week's PE cycle reads as a compressed breakout opportunity at 49.1, but the deterministic normalized valuation read is…
From the price. Price stage 2, week 9 — below its 200-day line, relative strength falling.
From the research. Earnings are recovering through specialty mix and calibrated pricing, but the trailing valuation rests on elevated margins and carries a peak-margin value-trap risk.
🚨 Where they disagree. The operating and price curves indicate early expansion with price below its prior peak. This week's PE cycle reads as a compressed breakout opportunity at 49.1, but the deterministic normalized valuation read is PEAK_MARGIN_VALUE_TRAP: operating margin is above its normalized level and the normalized valuation is materially less inexpensive.
What is proven. Earnings are recovering through specialty mix and calibrated pricing, but the trailing valuation rests on elevated margins and carries a peak-margin value-trap risk.
What is not proven yet. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure.
🚨 What would change our mind. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure.
🚨 Layer 1 read, 22 August 2026 — DROP. The 20.8% profit jump is three-quarters non-operating income, on a revenue line that is shrinking. June-quarter sales were 1,063 crore against 1,057 crore a year earlier - essentially flat - yet profit was reported up 20.8%. Checking the quarter line by line, other income (treasury-type earnings, not the pesticide business) went from 39 crore to 74 crore, which supplied about 35 crore of the 47 crore rise in pre-tax profit; the actual operating profit rose only from 219 to 233 crore. Meanwhile the full year of sales is DOWN 3.6% and the timeline itself admits this other-income question is unresolved, so the cheap-looking valuation is a fair price for a shrinking top line rather than a bargain waiting to be noticed.
What would change Layer 1’s mind. A single clean quarter would flip this: Q2 FY27 showing revenue GROWING year on year against the 930 Cr September-2025 base with operating margin at or above 20% AND other income back inside its 21-39 Cr trailing range - that would prove the recovery is operating rather than treasury and remove the value-trap read entirely. The mirror image, sharpened from the timeline's own falsification line, takes this to DROP: operating margin slipping below 20% for two consecutive quarters while revenue…
The test written in advance. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure. — the thesis as written as stated by the next result.
The test written in advance. Peak-margin valuation trap — Peak-margin valuation trap Operating margin at or below the normalized level for two reported quarters. by the next result.
The test written in advance. Monsoon and farm-demand volatility — Monsoon and farm-demand volatility Domestic revenue declines year on year during the Kharif quarter. by the next result.
What the company does. The latest quarter combined higher revenue, profit and operating margin with no flagged one-off in the results ledger. New products, herbicides and price actions are the named demand and margin levers. The investment case breaks if pricing and mix cannot defend margins through the monsoon-sensitive season.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| Specialty and herbicide mix | in play | — | Specialty products and herbicides are the principal revenue-mix levers. | Specialty launches do not gain repeat demand or channel returns rise. |
| Calibrated price pass-through | in play | — | Successive product-specific price actions are intended to protect margins from input and freight inflation. | Farmer demand weakens after price increases or competitors discount aggressively. |
| Innovation access from parent | in play | — | India's higher testing role can shorten the path from parent technology to local launches. | Testing does not convert into registrations and commercial launches. |
| Self-funded backward integration | in play | — | Cash generation can fund Dahej and Tarapur projects without a financing dependency. | Projects are deferred again or capex does not create a cost or supply advantage. |
🚨 What the surface reading misses. The surface reading is: The trailing multiple appears inexpensive versus its own history. The research reads it further: Current operating margin is above the normalized margin, so trailing earnings are above the mid-cycle earnings base used for valuation.
🚨 What the surface reading misses. The surface reading is: Cash generation broadly tracks reported earnings. The research reads it further: The multi-year result is supported by free cash generation, although latest-year conversion is lower because working capital absorbed cash.
Lever 2 · Value-added mix — BUILDING. Specialty products and herbicides are the principal revenue-mix levers. What proves it keeps working: Specialty and herbicide mix. It stops working if Specialty launches do not gain repeat demand or channel returns rise.
Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sumitomo Chemical India Ltd reported ₹1,063 Cr of revenue in the Jun 26 quarter, +0.6% year on year. That is the 2nd straight quarter of year-on-year growth. Over 8 years it has compounded at 6.8% a year. The last full year, FY26, came in at ₹3,238 Cr. The last four reported quarters add to ₹3,245 Cr.
Why this happened. Management links margin expansion to specialty mix, with recently launched products becoming a larger part of domestic revenue. Herbicide growth and branded formulations provide evidence that this is a product-mix story rather than only broad pricing.
FY26 revenue came in at ₹3,238 Cr (+2.8% on the year), capping 8 years at 6.8% compound. The latest quarter (Jun 26) printed ₹1,063 Cr, +0.6% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged −4.0% growth against the decade's 6.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −3.6% over the last 4 quarters against +4.7%/yr over the last 8 — rolling over; TTM profit +3.9% vs +15.5%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sumitomo Chemical India Ltd's operating margin is 22.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 9 fiscal years the operating margin has ranged 11.0% to 21.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 22.0%, +1.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 11.0%–21.0%, and FY26's 21.0% is the top of that band — a record year.
Why the margin moved: operating margin went +1.2 pp year on year while gross margin went +1.1 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sumitomo Chemical India Ltd earned ₹215 Cr of net profit in the Jun 26 quarter, +20.8% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹543 Cr. The 8-year compound rate is 17.9%. That is 20.2% of the quarter's revenue. The same quarter a year earlier earned ₹178 Cr.
Jun 26 profit was ₹215 Cr, +20.8% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹543 Cr (+7.3%), and the 8-year compound rate is 17.9%.
Why profit moved: revenue contributed +0.6% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +2.9% vs revenue −4.0%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 117% of Sumitomo Chemical India Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹446 Cr of operating cash against ₹543 Cr of profit. After ₹79.0 Cr of capital spending, ₹367 Cr was left as free cash.
Why this happened. The cash record shows free cash generation over the multi-year window and management describes internal cash and retained earnings as the capex funding source. The Capex Inflection Point model applies only after project commissioning and revenue conversion.
FY26: operating cash of ₹446 Cr against reported profit of ₹543 Cr, leaving free cash of ₹367 Cr after ₹79.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 117% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 117%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sumitomo Chemical India Ltd's cash conversion cycle runs 163 days in FY26, up from 157 days in FY21. Capital spending ran ₹290 Cr over the last 3 years. At FY26 sales of ₹3,238 Cr each day of that cycle holds about ₹8.9 Cr, so roughly ₹1,446 Cr sits inside the business at any moment.
FY26: debtors at 83 days, inventory at 166 days — roughly 5.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 163 days, looser than FY21's 157.
The full loop: cash goes out to suppliers and production on day 0; stock waits 166 days to sell; customers pay about 83 days after that; and suppliers themselves are paid at 86 days — netting out to the 163-day cycle.
In money terms: at FY26 sales of ₹3,238 Cr, each day of the cycle holds about ₹8.9 Cr — so the 163-day loop keeps roughly ₹1,446 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹290 Cr over the last 3 fiscal years against ₹194 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹20.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Sumitomo Chemical India Ltd earns a ROCE of 22% in FY26. That is up from a trough of 20% in FY24. Return on invested capital clears the cost of that capital by +9.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 16.8% net margin on 0.72× asset turns.
FY26 ROCE is 22%, recovered from a FY24 trough of 20% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 16.8% net margin × 0.72× asset turns × 1.32× balance-sheet leverage ≈ 16.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 21.3% − 12.0% = a +9.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Sumitomo Chemical India Ltd carries total debt of ₹63.0 Cr against shareholder equity of ₹3,394 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.02 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹63.0 Cr against shareholder equity of ₹3,394 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.02 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 2.2 points of Sumitomo Chemical India Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 9.3% of the company. Promoters moved +0.0 points over the same window, to 75.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +2.2 points over 8 quarters to 9.3%; Promoters: +0.0 points over 8 quarters to 75.0%; Foreign institutions: +0.0 points over 8 quarters to 3.0%.
Why the register moved: domestic institutions drove it (+2.2 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sumitomo Chemical India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sumitomo Chemical India Ltd trades at 41.6× P/E, near the bottom of its own range — cheaper only 11% of the time. Its long-run median P/E is 51.6×, measured across 6.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 41.6× is near the bottom of its own range — cheaper only 11% of the time, against a long-run median of 51.6× measured over 6.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +7.4% against a −14.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +3.1%/yr price move, ~+9.0%/yr came from earnings growth and ~−5.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sumitomo Chemical India Ltd reads as consistent on its fundamental arc. Consistent — profit and EPS growth have stayed positive through the window, with ROCE at 22.7% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +2.8% | −2.7% | +4.1% | — |
| Profit | +7.3% | +2.7% | +9.5% | — |
| EPS | +7.4% | +2.6% | +9.5% | — |
| Share price | −14.1% | +2.4% | +3.1% | — |
4-Factor Sector Score
46.2/100 — rank 12 of 24 in Pesticides/Agrochemicals · 94% evidence confidence
Sumitomo Chemical India Ltd scores 46.2 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 12. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 12.6 + 19 + 5.5 + 9.1 = 46.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Sumitomo Chemical India Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
🚨 Dahej Project Timeline Slippage · 28 October 2025. The timeline for the strategic Dahej greenfield project has been pushed back without explanation. In the May 2025 call, management stated initial manufacturing would deliver products starting in 2027. However, in the October 2025 call, the first revenue from the project is now expected in 2028, representing a delay of at least one year for this key growth initiative. Earlier call (May 2025): “we want to start manufacturing certain products to deliver between”. Later call (Oct 2025): “we expect that during this current financial year some of these project should go and get approved... with implementation timelines of 18 months to two years. So maybe sometime in calendar year 2028 we see that that some of these projects should start generating revenues.”
Contradictory Latin America Export Outlook · 28 October 2025. Management's assessment of the Latin American (LATAM) export market has reversed from positive to negative. In May 2025, after a sluggish quarter, management stated the LATAM market was 'coming back on track'. However, in the October 2025 call, they reported that demand from the region has 'muted' with 'pressure on the channel,' indicating a significant negative shift. Earlier call (May 2025): “LATAM picked up early last year... In the Quarter 4, it did went a little bit sluggish. But based on our market information and all, it seems to be coming back on track. We need to wait for one or two more quarters to really see it to come back to normalcy. We are optimistic.” Later call (Oct 2025): “In exports demand has muted in certain geographies specifically in Africa, countries like Kenya, Ethiopia and in Latin America, primarily due to Brazil, due to shipment difference.”
🚨 Delay in Blockbuster Product Manufacturing · 28 October 2025. The timeline for local manufacturing of the new 'blockbuster' product, Excalia Max, has been materially delayed. In May 2025, management guided for production to begin at the Tarapur facility within '12 to 15 months' (i.e., by mid-2026). This timeline was pushed out significantly in the October 2025 call, with completion now expected by March 2027. Earlier call (May 2025): “technical or the active ingredient... for this newly launched globally blockbuster product will also be made by us in India within next 12 to 15 months. This will be made in our existing Tarapur plant.” Later call (Oct 2025): “We are investing about say 8 to 10 crore rupees at our Tarapur site and the Tarapur site will be able to make this product for Indian requirement in the near future. We expect that by March 2027 that project should get completed.”
Shift in Sustainable Margin Profile · 28 October 2025. The company's view of its sustainable EBITDA margin has materially changed from the guidance provided a year ago. In October 2024, management was firm that a realistic full-year EBITDA margin range was 18-20%. However, in the October 2025 call, they reported a 22% EBITDA margin for H1 FY26 and described it as 'broadly in line with our expectations', contradicting the previously established ceiling. Earlier call (Oct 2024): “on a full year basis, keeping in mind all the factors... we should somewhere be in the similar range, 18% to 20% kind of EBITDA level margins.” Later call (Oct 2025): “The Ebitda margin stood at 22% for H1 FY26, broadly in line with our expectations despite the adverse seasonal impact in Q2 and the half year level ACL performance reflects healthy underlying strength.”
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Bayer CropScience LtdBAYERCROP | 71.8/100Favorable setup94% evidence | BASING | 22.9/35 Revenue -2.8% · PAT 23.8% · OPM change 2 pp 100% evidence | 21.2/25 ROCE 29.1% · OPM 20% 100% evidence | 14.7/20 P/E 24.4× · PEG 1.28 100% evidence | 13.0/20 RS sector 9.4% · RS bench -11% · 1Y -21.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.9 + 21.2 + 14.7 + 13 = 71.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Titan Biotech Ltd524717 | 68.9/100Favorable setup82% evidence | ASLEEP | 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 2 pp 95% evidence | 20.1/25 ROCE 22.8% · OPM 21% 76% evidence | 5.7/20 P/E 53.3× · PEG — 50% evidence | 14.0/20 RS sector 35.7% · RS bench 34.4% · 1Y 213.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 20.1 + 5.7 + 14 = 68.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Sharda Cropchem LtdSHARDACROP | 64.7/100Mixed-positive evidence100% evidence | BASING | 24.2/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 100% evidence | 19.6/25 ROCE 30.2% · OPM 17% 100% evidence | 18.7/20 P/E 11× · PEG 0.26 100% evidence | 2.2/20 RS sector -14.6% · RS bench -15.4% · 1Y -16.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 19.6 + 18.7 + 2.2 = 64.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.6% and the one-year return is -16.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 4Dharmaj Crop Guard LtdDHARMAJ | 63.2/100Mixed-positive evidence74% evidence | BASING | 21.1/35 Revenue 8.5% · PAT 13.2% · OPM change 1 pp 95% evidence | 15.9/25 ROCE 16.8% · OPM 15% 95% evidence | 10.9/20 P/E 15.1× · PEG — 15% evidence | 15.3/20 RS sector 5% · RS bench 4.5% · 1Y -27.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.1 + 15.9 + 10.9 + 15.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Punjab Chemicals & Crop Protection LtdPUNJABCHEM | 60.5/100Mixed-positive evidence81% evidence | BREAKING OUT | 23.4/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 17.9/25 ROCE 18.6% · OPM 12% 95% evidence | 11.6/20 P/E 19.5× · PEG — 50% evidence | 7.6/20 RS sector -6.2% · RS bench -5.8% · 1Y -4.2%5 of 10 weeks ahead 70% evidence |
| Exact sum: 23.4 + 17.9 + 11.6 + 7.6 = 60.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 56.9/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.3/35 Revenue 48.4% · PAT 81.5% · OPM change 1 pp 95% evidence | 14.8/25 ROCE 19.6% · OPM 11% 95% evidence | 10.8/20 P/E 15.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence |
| Exact sum: 21.3 + 14.8 + 10.8 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7India Pesticides LtdIPL | 52.9/100Mixed-positive evidence81% evidence | BASING | 20.1/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.7/25 ROCE 16.6% · OPM 14% 95% evidence | 14.1/20 P/E 14.3× · PEG — 50% evidence | 5.0/20 RS sector -11.9% · RS bench -17.5% · 1Y -35.3%1 of 11 weeks ahead 70% evidence |
| Exact sum: 20.1 + 13.7 + 14.1 + 5 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Bhagiradha Chemicals & Industries LtdBHAGCHEM | 51.9/100Mixed-positive evidence100% evidence | ASLEEP | 29.1/35 Revenue 33.7% · PAT 100% · OPM change 9 pp 100% evidence | 7.0/25 ROCE 4.5% · OPM 16% 100% evidence | 1.6/20 P/E 122× · PEG 8.06 100% evidence | 14.2/20 RS sector 9.1% · RS bench 7.6% · 1Y -4.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 7 + 1.6 + 14.2 = 51.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Rallis India LtdRALLIS | 50.9/100Mixed-positive evidence94% evidence | BASING | 20.4/35 Revenue 4.4% · PAT 24.4% · OPM change 2 pp 100% evidence | 10.6/25 ROCE 14.1% · OPM 18% 100% evidence | 11.5/20 P/E 17.2× · PEG 2.15 100% evidence | 8.4/20 RS sector -1.8% · RS bench -19% · 1Y -43.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 10.6 + 11.5 + 8.4 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Astec Lifesciences LtdASTEC | 50.9/100Mixed-positive evidence69% evidence | BASING | 23.9/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 3.2/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.8/20 RS sector 5.1% · RS bench 3.6% · 1Y -17.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 3.2 + 10 + 13.8 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Jubilant Ingrevia LtdJUBLINGREA | 50.5/100Mixed-positive evidence93% evidence | TURNING | 19.0/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.4% · OPM 15% 100% evidence | 6.1/20 P/E 33× · PEG 2.41 65% evidence | 14.8/20 RS sector 0.7% · RS bench -0.6% · 1Y -8.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 10.6 + 6.1 + 14.8 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Sumitomo Chemical India Ltdthis pageSUMICHEM | 46.2/100Mixed-negative evidence94% evidence | FADING | 12.6/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 5.5/20 P/E 41.6× · PEG 4 100% evidence | 9.1/20 RS sector -8.2% · RS bench 3.2% · 1Y -16.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 19 + 5.5 + 9.1 = 46.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13NACL Industries LtdNACLIND | 45.9/100Mixed-negative evidence100% evidence | ASLEEP | 29.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 3.9/25 ROCE 8.1% · OPM 11% 100% evidence | 3.7/20 P/E 142× · PEG 2.02 100% evidence | 9.2/20 RS sector -4.3% · RS bench -5.8% · 1Y -35%7 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 3.9 + 3.7 + 9.2 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Meghmani Organics LtdMOL | 45.8/100Mixed-negative evidence74% evidence | BREAKING OUT | 20.8/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 7.8/25 ROCE 6.7% · OPM 18% 95% evidence | 9.4/20 P/E 24.8× · PEG — 15% evidence | 7.8/20 RS sector -33.7% · RS bench 7.6% · 1Y -22%7 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 7.8 + 9.4 + 7.8 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Excel Industries LtdEXCELINDUS | 42.8/100Mixed-negative evidence74% evidence | TURNING | 12.4/35 Revenue 5.5% · PAT -20.4% · OPM change 0 pp 95% evidence | 10.3/25 ROCE 6.2% · OPM 14% 95% evidence | 10.4/20 P/E 17.3× · PEG — 15% evidence | 9.7/20 RS sector -4.6% · RS bench 1.7% · 1Y -15.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 10.3 + 10.4 + 9.7 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16UPL LtdUPL | 42.2/100Mixed-negative evidence91% evidence | BASING | 17.1/35 Revenue 12.9% · PAT 98.4% · OPM change -2 pp 74% evidence | 8.3/25 ROCE 10.1% · OPM 13% 100% evidence | 12.2/20 P/E 24.5× · PEG 0.5 100% evidence | 4.6/20 RS sector -11.6% · RS bench -12.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 8.3 + 12.2 + 4.6 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Bharat Rasayan LtdBHARATRAS | 41.9/100Mixed-negative evidence87% evidence | ASLEEP | 10.8/35 Revenue -5.2% · PAT 3.6% · OPM change -3 pp 95% evidence | 13.6/25 ROCE 16% · OPM 15% 95% evidence | 14.4/20 P/E 13.2× · PEG — 50% evidence | 3.1/20 RS sector -32.8% · RS bench -34% · 1Y -53.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.8 + 13.6 + 14.4 + 3.1 = 41.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Epigral LtdEPIGRAL | 41.2/100Mixed-negative evidence94% evidence | TURNING | 7.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.5/25 ROCE 15.5% · OPM 25% 100% evidence | 14.4/20 P/E 18× · PEG 0.43 100% evidence | 4.8/20 RS sector -32.9% · RS bench -6.6% · 1Y -35.9%1 of 10 weeks ahead 70% evidence |
| Exact sum: 7.5 + 14.5 + 14.4 + 4.8 = 41.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Dhanuka Agritech LtdDHANUKA | 40.8/100Mixed-negative evidence100% evidence | BASING | 6.6/35 Revenue -5.6% · PAT -12.1% · OPM change -4 pp 100% evidence | 16.2/25 ROCE 23.8% · OPM 12% 100% evidence | 11.4/20 P/E 16.3× · PEG 1.72 100% evidence | 6.6/20 RS sector -11% · RS bench -12.4% · 1Y -38.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.6 + 16.2 + 11.4 + 6.6 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Best Agrolife LtdBESTAGRO | 40.0/100Mixed-negative evidence87% evidence | TURNING | 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.1/25 ROCE 5.2% · OPM 20% 95% evidence | 8.8/20 P/E 22.8× · PEG — 50% evidence | 14.2/20 RS sector -0.4% · RS bench -1.8% · 1Y -27.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 9.1 + 8.8 + 14.2 = 40 · Decision use: Price leads the evidence: RS versus the benchmark is -1.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Insecticides India LtdINSECTICID | 37.6/100Mixed-negative evidence87% evidence | BASING | 10.7/35 Revenue 1.3% · PAT -16.7% · OPM change -1 pp 95% evidence | 10.8/25 ROCE 15.8% · OPM 11% 95% evidence | 11.5/20 P/E 14.2× · PEG — 50% evidence | 4.6/20 RS sector -6.7% · RS bench -8% · 1Y -23.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 10.8 + 11.5 + 4.6 = 37.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22P I Industries LtdPIIND | 35.3/100Mixed-negative evidence94% evidence | BASING | 4.7/35 Revenue -16.6% · PAT -27.8% · OPM change -5 pp 100% evidence | 13.8/25 ROCE 15% · OPM 22% 100% evidence | 9.5/20 P/E 31.7× · PEG 1.71 100% evidence | 7.3/20 RS sector -3.4% · RS bench -25.1% · 1Y -38.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 4.7 + 13.8 + 9.5 + 7.3 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Heranba Industries LtdHERANBA | 28.0/100Adverse evidence77% evidence | BASING | 8.9/35 Revenue -2.6% · PAT -80% · OPM change 5.9 pp 95% evidence | 2.8/25 ROCE -1.7% · OPM 12.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.3/20 RS sector -19% · RS bench -20.3% · 1Y -48.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.9 + 2.8 + 10 + 6.3 = 28 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24GSP Crop Science LtdGSPCROP | 47.7/100Thin evidence · provisional38% evidence | BREAKING OUT | 14.2/35 Revenue — · PAT — · OPM change 0 pp 45% evidence | 13.6/25 ROCE 18.9% · OPM 11% 76% evidence | 9.9/20 P/E 21× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 9 weeks ahead 0% evidence |
| Exact sum: 14.2 + 13.6 + 9.9 + 10 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Sumitomo Chemical India Ltd's share price today?
Sumitomo Chemical India Ltd trades at ₹476, −14.1% over the past year. The company is valued at ₹23,779 Cr. The stock sits at 53% of its 52-week range of ₹375–₹565, −1.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 9 weeks in. — as of 11 September 2026.
What were Sumitomo Chemical India Ltd's latest quarterly results?
Sumitomo Chemical India Ltd reported revenue of ₹1,063 Cr and net profit of ₹215 Cr for the Jun 26 quarter. Revenue rose 0.6% and profit rose 20.8% year on year. Earnings per share were ₹4.30. The operating margin was 22.0%, 1.0 pp higher than a year earlier. — as of 11 September 2026.
What is Sumitomo Chemical India Ltd's revenue?
Sumitomo Chemical India Ltd reported revenue of ₹1,063 Cr in the Jun 26 quarter, +0.6% year on year. For the full FY26 fiscal year, revenue was ₹3,238 Cr (+2.8%). Over the last 8 years revenue compounded at 6.8% a year. — as of 11 September 2026.
What is Sumitomo Chemical India Ltd's profit?
Sumitomo Chemical India Ltd earned ₹215 Cr of net profit in the Jun 26 quarter, +20.8% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹543 Cr. The operating margin ran 22.0% in the latest quarter. — as of 11 September 2026.
What is Sumitomo Chemical India Ltd's market cap?
Sumitomo Chemical India Ltd's market capitalisation is ₹23,779 Cr at a share price of ₹476. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Sumitomo Chemical India Ltd's P/E ratio?
Sumitomo Chemical India Ltd trades at a P/E of 41.6×, at the 11th percentile of its own 6-year range, against a long-run median of 51.6×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Sumitomo Chemical India Ltd pay a dividend?
Yes — Sumitomo Chemical India Ltd's dividend payout was 12% of profit in FY26, and it recorded a payout in 8 of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Sumitomo Chemical India Ltd overvalued?
On its own history, Sumitomo Chemical India Ltd looks cheap: its P/E of 41.6× has been cheaper only 11% of the time in 6 years (long-run median 51.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 11 September 2026.
Is Sumitomo Chemical India Ltd growing?
Yes — Sumitomo Chemical India Ltd is growing: latest-quarter revenue +0.6% year on year, profit +20.8%, and the margin +1.0 pp at 22.0%. The 8-year compound rates are 6.8% (revenue) and 17.9% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Sumitomo Chemical India Ltd performing?
Sumitomo Chemical India Ltd is in a confirmed uptrend, 9 weeks in. Its latest quarter's revenue rose 0.6% and profit rose 20.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 10 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Sumitomo Chemical India Ltd in?
Consistent — profit and EPS growth have stayed positive through the window, with ROCE at 22.7% and holding. The read comes from the last 12 quarters of growth (revenue growth −3.6% latest, profit growth +3.9% latest, eps growth +4.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Sumitomo Chemical India Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 9 of stage 2), trading −1.5% versus its 200-day average and at 53% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Sumitomo Chemical India Ltd beating the market?
On recent form, yes — Sumitomo Chemical India Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 10 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 6.6 years the stock moved +106% against the NIFTY 500's +130% — behind the index over the full window. — as of 11 September 2026.
Will Sumitomo Chemical India Ltd's share price go up?
This page publishes no price forecast for Sumitomo Chemical India Ltd. What it measures instead: the share price is ₹476, the price is in a confirmed uptrend 9 weeks in. Its P/E of 41.6× sits at the 11th percentile of its own 6-year range. — as of 11 September 2026.
Who owns Sumitomo Chemical India Ltd?
Promoters hold 75.0% of Sumitomo Chemical India Ltd, foreign institutions 3.0%, domestic institutions 9.3% and the public 12.7% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 2.2 points over 8 quarters. — as of 11 September 2026.
Does Sumitomo Chemical India Ltd have too much debt?
No — Sumitomo Chemical India Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill 84×. FY26 borrowings were ₹63.0 Cr against equity of ₹3,390 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Sumitomo Chemical India Ltd's capex?
Sumitomo Chemical India Ltd spent ₹290 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹79.0 Cr, with ₹20.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Sumitomo Chemical India Ltd's cash flow?
Sumitomo Chemical India Ltd generated ₹446 Cr of operating cash flow in FY26 and ₹367 Cr of free cash flow after ₹79.0 Cr of capital spending. Reported profit that year was ₹543 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Sumitomo Chemical India Ltd's profit real cash?
Yes — over the last 3 fiscal years, 117% of Sumitomo Chemical India Ltd's reported profit arrived as operating cash. Though the latest year ran at 82% — the trend is the thing to watch. In FY26, operating cash was ₹446 Cr against reported profit of ₹543 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Sumitomo Chemical India Ltd in its business cycle?
Sumitomo Chemical India Ltd's FY26 operating margin was 21.0%, against a 9-year band of 11.0%–21.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 22.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Sumitomo Chemical India Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Sumitomo Chemical India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sumitomo Chemical India Ltd is coiled. The quarters are improving, yet the P/E sits at the 11th percentile of its own 6-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!